Non-Hodgkin lymphoma (NHL) comprises a wide spectrum of lymphoid neoplasms that affect approximately 1.5 million people worldwide. B cell lymphomas (BCLs) account for the majority (>85%) of cases of NHL; the others are derived from T cells or natural killer cells. NHL is frequently categorized by prognosis into slow-progressing or indolent NHL (iNHL), or fast-progressing or aggressive NHL (aNHL). Follicular lymphoma (FL) and diffuse large BCL (DLBCL) are the most common indolent and aggressive subtypes, respectively, and account for around one-fifth and one-third of NHL cases each.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Competing Interests
The authors declare no competing interests.